0001193125-22-198105.txt : 20220720 0001193125-22-198105.hdr.sgml : 20220720 20220720160856 ACCESSION NUMBER: 0001193125-22-198105 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220718 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20220720 DATE AS OF CHANGE: 20220720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 221094319 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 d306766d8k.htm 8-K 8-K
false 0001840574 0001840574 2022-07-18 2022-07-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 18, 2022

 

 

Verve Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40489   82-4800132
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

500 Technology Square, Suite 901

Cambridge, Massachusetts

  02139
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 603-0070

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol(s)

 

Name of each exchange

on which registered

Common stock, $0.001 par value per share   VERV   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


Item 1.01

Entry Into a Material Definitive Agreement.

On July 18, 2022 (the “Effective Date”), Verve Therapeutics, Inc. (“Verve” or the “Company”) entered into a Strategic Collaboration and License Agreement (the “Collaboration Agreement”) with Vertex Pharmaceuticals Incorporated (“Vertex”) for an exclusive, four-year worldwide research collaboration focused on developing in vivo gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Additionally, on the Effective Date, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Vertex, pursuant to which the Company agreed to sell and issue shares of its common stock to Vertex.

Strategic License and Collaboration Agreement

Pursuant to the Collaboration Agreement, Verve will be responsible for discovery, research and certain preclinical development of novel in vivo gene editing development candidates for the target of interest. Verve’s research activities will be focused on (i) identifying and engineering specific gene editing systems and in vivo delivery systems directed to the target and (ii) evaluating and optimizing development candidates to achieve criteria specified in the Collaboration Agreement. Vertex will reimburse Verve’s research expenses consistent with an agreed-upon budget. The research term has an initial term of four years and may be extended by Vertex for up to one additional year.

Vertex will be solely responsible for subsequent development, manufacturing and commercialization of any product candidate resulting from Verve’s research efforts. Verve received an upfront payment from Vertex of $25 million on July 20, 2022. Verve is eligible to receive (i) success payments of up to $22 million for each product candidate (up to a maximum of $66 million) that achieves the applicable development criteria and (ii) up to an aggregate of $340 million in development and commercial milestone payments. Verve is also eligible to receive tiered single-digit royalties on net sales, subject to specified reductions. Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) ten years after the first commercial sale of such product in such country.

Prior to the first patient dosing of the first Phase 1 clinical trial for the first product candidate developed under the Collaboration Agreement, Verve also has the right to opt-in to a profit share arrangement pursuant to which Vertex and Verve would share the costs and net profits for all product candidates emerging from the collaboration. If Verve exercises its opt-in right, in lieu of milestones and royalties, Verve will be obligated to pay for a specified percentage of the development and commercialization costs, and it will have the right to receive a specified percentage of the profits from any sales of any product candidates advanced under the collaboration. At the time Verve exercises the option, it may elect a profit/cost share of up to 40% (with Vertex retaining a minimum of 60%). In order to exercise its opt-in right, Verve is required to pay a fee ranging from $25-70 million, depending on the profit/cost percentage elected by Verve and the licensed technology of Verve included in the most advanced product candidate at the time Verve exercises its opt-in right. Under all profit share scenarios, Vertex will control the worldwide development and commercialization of any product candidates resulting from the collaboration.

The Collaboration Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. Verve and Vertex each have the right to terminate the agreement for material breach by, or insolvency of, the other party following notice, and if applicable, a cure period. Vertex may also terminate the Collaboration Agreement in its entirety for convenience upon 90 days’ notice.

The foregoing description of the terms of the Collaboration Agreement is qualified in its entirety by reference to the full text of the Collaboration Agreement, a copy of which Verve intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2022.

Stock Purchase Agreement

On the Effective Date, in connection with the execution of the Collaboration Agreement, Verve and Vertex also entered into the Stock Purchase Agreement for the sale and issuance of 1,519,756 shares of Verve’s common stock, par value $0.001 per share (the “Shares”) to Vertex at a price of $23.03 per share, which is equal to the five-day volume-weighted average share price as of July 15, 2022, for an aggregate purchase price of $35.0 million. The sale of the Shares closed on July 20, 2022.

 


The Stock Purchase Agreement includes lock-up restrictions with respect to the Shares. Pursuant to the terms of the Stock Purchase Agreement, Vertex has agreed not to, and to cause its affiliates not to, sell or transfer any of the Shares for a period of 12 months following the date of issuance of the Shares, subject to specified conditions and exceptions.

The foregoing description of the terms of the Stock Purchase Agreement is qualified in its entirety by reference to the full text of the Stock Purchase Agreement, a copy of which Verve intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2022.

 

Item 3.02

Unregistered Sales of Equity Securities.

The information set forth in Item 1.01 above under the caption “Stock Purchase Agreement” is incorporated herein by reference. The Company expects the Shares to be issued in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    VERVE THERAPEUTICS, INC.
Date: July 20, 2022     By:  

/s/ Andrew Ashe

      Name: Andrew Ashe
      Title: President and Chief Operating Officer
EX-101.SCH 2 verv-20220718.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 verv-20220718_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 verv-20220718_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jul. 18, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001840574
Document Type 8-K
Document Period End Date Jul. 18, 2022
Entity Registrant Name Verve Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40489
Entity Tax Identification Number 82-4800132
Entity Address, Address Line One 500 Technology Square
Entity Address, Address Line Two Suite 901
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (617)
Local Phone Number 603-0070
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, $0.001 par value per share
Trading Symbol VERV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 d306766d8k_htm.xml IDEA: XBRL DOCUMENT 0001840574 2022-07-18 2022-07-18 false 0001840574 8-K 2022-07-18 Verve Therapeutics, Inc. DE 001-40489 82-4800132 500 Technology Square Suite 901 Cambridge MA 02139 (617) 603-0070 false false false false Common stock, $0.001 par value per share VERV NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d306766d8k.htm verv-20220718.xsd verv-20220718_lab.xml verv-20220718_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d306766d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d306766d8k.htm" ] }, "labelLink": { "local": [ "verv-20220718_lab.xml" ] }, "presentationLink": { "local": [ "verv-20220718_pre.xml" ] }, "schema": { "local": [ "verv-20220718.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "verv", "nsuri": "http://www.vervetx.com/20220718", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d306766d8k.htm", "contextRef": "duration_2022-07-18_to_2022-07-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d306766d8k.htm", "contextRef": "duration_2022-07-18_to_2022-07-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220718/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-22-198105-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-198105-xbrl.zip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end